James E Tisdale1,2, Heather A Jaynes1, Brian R Overholser1,2, Kevin M Sowinski1,2, David A Flockhart2, Richard J Kovacs3. 1. Department of Pharmacy Practice, College of Pharmacy, Purdue University, Indianapolis, Indiana. 2. Division of Clinical Pharmacology, Department of Medicine, School of Medicine, Indiana University, Indianapolis, Indiana. 3. Krannert Institute of Cardiology, Department of Medicine, School of Medicine, Indiana University, Indianapolis, Indiana.
Abstract
OBJECTIVES: We tested the hypothesis that oral progesterone administration attenuates drug-induced QT interval lengthening. BACKGROUND: Evidence from preclinical and human investigations suggests that higher serum progesterone concentrations may be protective against drug-induced QT interval lengthening. METHODS: In this prospective, double-blind, crossover study, 19 healthy female volunteers (21-40 years) were randomized to receive progesterone 400 mg or matching placebo orally once daily for 7 days timed to the menses phase of the menstrual cycle (between-phase washout period = 49 days). On day 7, ibutilide 0.003 mg/kg was infused over 10 minutes, after which QT intervals were recorded and blood samples collected for 12 hours. Prior to the treatment phases, subjects underwent ECG monitoring for 12 hours to calculate individualized heart rate-corrected QT intervals (QTcI). RESULTS:Fifteen subjects completed all study phases. Maximum serum ibutilide concentrations in the progesterone and placebo phases were similar (1247±770 vs 1172±709 pg/mL, p=0.43). Serum progesterone concentrations were higher during the progesterone phase (16.2±11.0 vs 1.2±1.0 ng/mL, p<0.0001), while serum estradiol concentrations in the two phases were similar (89.3±62.8 vs 71.8±31.7 pg/mL, p=0.36). Pre-ibutilide lead II QTcI was significantly lower in the progesterone phase (412±15 vs 419±14 ms, p=0.04). Maximum ibutilide-associated QTcI (443±17 vs 458±19 ms, p=0.003), maximum percent increase in QTcI from pretreatment value (7.5±2.4 vs 9.3±3.4%, p=0.02) and area under the effect (QTcI) curve during the first hour post-ibutilide (497±13 vs 510±16 ms-hr, p=0.002) were lower during the progesterone phase. Progesterone-associated adverse effects included fatigue/malaise and vertigo. CONCLUSIONS:Oral progesterone administration attenuates drug-induced QTcI lengthening.
RCT Entities:
OBJECTIVES: We tested the hypothesis that oral progesterone administration attenuates drug-induced QT interval lengthening. BACKGROUND: Evidence from preclinical and human investigations suggests that higher serum progesterone concentrations may be protective against drug-induced QT interval lengthening. METHODS: In this prospective, double-blind, crossover study, 19 healthy female volunteers (21-40 years) were randomized to receive progesterone 400 mg or matching placebo orally once daily for 7 days timed to the menses phase of the menstrual cycle (between-phase washout period = 49 days). On day 7, ibutilide 0.003 mg/kg was infused over 10 minutes, after which QT intervals were recorded and blood samples collected for 12 hours. Prior to the treatment phases, subjects underwent ECG monitoring for 12 hours to calculate individualized heart rate-corrected QT intervals (QTcI). RESULTS: Fifteen subjects completed all study phases. Maximum serum ibutilide concentrations in the progesterone and placebo phases were similar (1247±770 vs 1172±709 pg/mL, p=0.43). Serum progesterone concentrations were higher during the progesterone phase (16.2±11.0 vs 1.2±1.0 ng/mL, p<0.0001), while serum estradiol concentrations in the two phases were similar (89.3±62.8 vs 71.8±31.7 pg/mL, p=0.36). Pre-ibutilide lead II QTcI was significantly lower in the progesterone phase (412±15 vs 419±14 ms, p=0.04). Maximum ibutilide-associated QTcI (443±17 vs 458±19 ms, p=0.003), maximum percent increase in QTcI from pretreatment value (7.5±2.4 vs 9.3±3.4%, p=0.02) and area under the effect (QTcI) curve during the first hour post-ibutilide (497±13 vs 510±16 ms-hr, p=0.002) were lower during the progesterone phase. Progesterone-associated adverse effects included fatigue/malaise and vertigo. CONCLUSIONS: Oral progesterone administration attenuates drug-induced QTcI lengthening.
Entities:
Keywords:
Electrocardiography; Hormonal therapy; Preventive; QT interval; Torsades de pointes
Authors: Melanie M Glover; David S McKenna; Cathy M Downing; Dana B Smith; Christopher S Croom; Jiri D Sonek Journal: Am J Perinatol Date: 2011-03-04 Impact factor: 1.862
Authors: Alan H Kadish; Philip Greenland; Marian C Limacher; William H Frishman; Sandra A Daugherty; Janice B Schwartz Journal: Ann Noninvasive Electrocardiol Date: 2004-10 Impact factor: 1.468
Authors: E H Locati; W Zareba; A J Moss; P J Schwartz; G M Vincent; M H Lehmann; J A Towbin; S G Priori; C Napolitano; J L Robinson; M Andrews; K Timothy; W J Hall Journal: Circulation Date: 1998-06-09 Impact factor: 29.690
Authors: James E Tisdale; Heather A Jaynes; Brian R Overholser; Kevin M Sowinski; Richard J Kovacs Journal: J Cardiovasc Electrophysiol Date: 2019-04-21
Authors: Elena Tomaselli Muensterman; Heather A Jaynes; Kevin M Sowinski; Brian R Overholser; Changyu Shen; Richard J Kovacs; James E Tisdale Journal: Circulation Date: 2019-09-23 Impact factor: 29.690
Authors: Jerilynn C Prior; Chiaki Konishi; Christine L Hitchcock; Elaine Kingwell; Patti Janssen; Anthony P Cheung; Nichole Fairbrother; Azita Goshtasebi Journal: Int J Environ Res Public Health Date: 2018-05-18 Impact factor: 3.390
Authors: Virginie Grouthier; Melissa Y Y Moey; Estelle Gandjbakhch; Xavier Waintraub; Christian Funck-Brentano; Anne Bachelot; Joe-Elie Salem Journal: Int J Mol Sci Date: 2021-02-02 Impact factor: 5.923